Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) appointed Elizabeth Laws, Ph.D. as Senior Vice President, Global Program Team Leader for KT-621, its first-in-class, oral STAT6 degrader for immunological diseases. She will guide global strategy and development.
KT-621 has parallel Phase 2b trials in atopic dermatitis and asthma, with data expected by year-end 2026 and late 2027, and Phase 3 atopic dermatitis trials planned by mid-2027.
Positive
- Appointment of Dr. Elizabeth Laws as SVP, KT-621 Development Program Leader
- KT-621 atopic dermatitis Phase 2b trial enrollment complete
- KT-621 asthma Phase 2b trial ongoing
- KT-621 Phase 2b data expected in atopic dermatitis by year-end 2026
- KT-621 asthma Phase 2b data expected by late 2027
- Phase 3 atopic dermatitis trials for KT-621 planned to start by mid-2027
Negative
- None.
Market reaction after KT-621 leadership change: KYMR +3.90% in the Jul 7 session
In the Jul 7 session, KYMR gained 3.90%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.2% during that session. Argus tracked a trough of -4.5% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Clinical trial update | Positive | +16.6% | Completed Phase 2b BROADEN2 enrollment early with AD data guided by year-end 2026. |
| Jun 24 | Leadership change | Positive | +16.6% | Appointed Felix J. Baker as Chairman while prior chair remained on the board. |
| Jun 12 | Clinical data | Positive | +3.5% | Presented favorable Phase 1 KT-621 data with high STAT6 degradation and tolerability. |
| Jun 09 | Clinical trial start | Positive | +0.2% | First participant dosed in Phase 1 KT-485 trial triggering collaboration milestone. |
| Jun 08 | Management hire | Neutral | +0.2% | Hired SVP Development Operations and announced COO retirement with advisory role. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially KT-621 clinical milestones and governance changes, has often coincided with strong positive price reactions for Kymera.
Key Terms
stat6 medical
targeted protein degradation technical
atopic dermatitis medical
type 2 inflammatory diseases medical
dupilumab medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program
KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027
WATERTOWN, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Elizabeth Laws, Ph.D., as Senior Vice President, KT-621 Development Program Leader. Dr. Laws brings more than two decades of biopharmaceutical leadership experience spanning R&D strategy, global clinical development, launch readiness, commercialization, and franchise expansion of groundbreaking medicines. In her role, she will lead the strategy and global development of KT-621, the Company’s first-in-class, oral STAT6 degrader.
“We are thrilled to welcome Liz to Kymera at a pivotal time for our company and the KT-621 program. With enrollment complete in our Phase 2b study in atopic dermatitis, our Phase 2b asthma study ongoing and preparations underway for initiation of registrational studies across multiple indications, Liz’s proven leadership will be essential,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “She brings exceptional experience across immunology clinical development, global franchise strategy and commercialization, including a track record of helping bring blockbuster therapies, such as dupilumab, to patients at scale. I look forward to partnering with her as we work to realize the potential of KT-621 as a paradigm-shifting oral therapy for multiple Type 2 inflammatory diseases.”
“I have spent my career working at the intersection of scientific innovation, development strategy and patient impact, and I see a tremendous opportunity at Kymera to help deliver a new generation of oral immunology medicines,” said Dr. Laws. “Targeted protein degradation has the potential to address critical gaps in the treatment landscape for immunological diseases. I look forward to working with the talented Kymera team to help realize the full potential of these programs for patients around the world.”
Prior to joining Kymera, Dr. Laws served as Senior Vice President, Head of Sanofi Integrated Launch & Commercialization Excellence, where she led enterprise-wide launch and commercialization strategy. Previously, she held multiple senior leadership roles at Sanofi, including Vice President, Head of the Immunology & Inflammation Therapeutic Area, and Vice President, Head of the Dupilumab/Dupixent® Development Program, where she led global development strategy and helped build dupilumab into a global franchise spanning dermatology, respiratory and gastroenterology indications. Earlier in her career, Dr. Laws held leadership roles across R&D operations, strategic planning and alliance management at Sanofi, served as Vice President, Chief of Project Operations at MDS Pharma, and was a consultant in McKinsey & Company’s Pharmaceuticals & Medical Products Practice. She was named one of Endpoints News 2023 Top 20 Women Leading Biopharma R&D. Dr. Laws received a PhD in Chemistry from the University of California, Berkeley, and Bachelor’s degrees in Chemistry and Mathematics from Williams College.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300
